Side Effects of Wegovy 1.0 mg: What Happens at This Stage of Treatment

What side effects do people typically notice at the 1.0 mg step?

Wegovy's titration schedule moves gradually upward (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg) with roughly four weeks at each level. By the time you reach 1.0 mg, your system has had two months on lower doses, starting from the wegovy 0.25 mg injection that begins the journey. That said, moving to a higher dose can bring a temporary return of gut symptoms, even in people who felt settled on 0.5 mg.

The most commonly reported effects are nausea, diarrhoea, constipation and indigestion. Burping, bloating and a feeling of fullness that arrives quickly during meals also feature. Fatigue and mild headaches are reported by some. These effects tend to peak in the first week or so after the dose increase, then settle. If they don't ease after two weeks, that's worth raising with your prescriber rather than pushing through quietly.

Less common but documented effects include low blood pressure on standing, heart rate changes and, occasionally, altered taste. The Mounjaro SmPC on the eMC is the reference clinicians use for the complete frequency-ranked list; the equivalent Wegovy document is worth reading if you want the full breakdown in manufacturer language. For a plain-English overview of the whole treatment journey, our Wegovy overview page covers the broader picture.

Are side effects different at 1.0 mg compared with the doses before it?

People who handled the 0.5 mg step well often handle 1.0 mg in a similar way, perhaps with a short-lived uptick in nausea. The mechanism doesn't change, semaglutide slows gastric emptying and acts on appetite centres in the brain, and both of those effects are slightly more pronounced as the dose rises.

What does tend to shift at 1.0 mg is appetite suppression. Many people notice it becomes more consistent here than it felt on 0.5 mg: the pull toward snacking between meals weakens, and portion sizes feel satisfying at a smaller volume. That's the therapeutic effect working. The gastrointestinal side effects and the appetite effects share the same underlying mechanism, which is why managing food choices (smaller, lower-fat meals, eating slowly, cutting alcohol) genuinely reduces symptom burden rather than just being advice to ignore.

If you experienced pronounced nausea at 0.5 mg that didn't settle, it may be worth revisiting that conversation before stepping up. How earlier doses feel is useful clinical information. For comparison, the side effects at the 0.5 mg stage follow a similar pattern but are typically milder.

When should you get medical help rather than wait it out?

Most side effects at this dose are uncomfortable rather than dangerous, and they improve. Some, however, require urgent attention.

Severe, persistent abdominal pain (especially pain that spreads toward the back and is accompanied by vomiting) may indicate acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update confirming pancreatitis as a known, infrequent but potentially serious effect of GLP-1 medicines; the advice is clear: get medical help promptly, not at your next scheduled review. Gallbladder problems are also reported with semaglutide, presenting as sharp pain in the upper right abdomen. Signs of dehydration from severe vomiting or diarrhoea (dizziness, very dark urine, not passing urine) need assessment too.

An allergic reaction (swelling of the face, lips or throat, difficulty breathing, a widespread rash) is rare but an emergency. Call 999 or go to A&E. For anything that concerns you but isn't an emergency, our support team is available seven days a week and can advise on whether something warrants escalation. The MHRA's Yellow Card scheme accepts reports from patients directly; if you experience something unexpected, reporting it contributes to the national safety picture for all users of this medicine.

How does the 1.0 mg experience shape what comes next in treatment?

How your body responds to 1.0 mg informs the clinical decision about moving to 1.7 mg. A prescriber reviewing your progress at this stage isn't just checking a box, they're weighing tolerability, any side effects that have persisted, and whether the dose is delivering the expected effect on appetite. That review happens before any increase, not after.

Some people stay at 1.0 mg longer than four weeks if tolerability is a concern, and our guide to wegovy 1 mg side effects covers what to monitor during that extended period. Others move to 1.7 mg on schedule. Neither path is better in the abstract; it depends on the individual. The side-effect profile at 1.7 mg is worth reading ahead of time so you know what to watch for if a step-up is coming.

At nume, every repeat order involves a clinical re-review before it's processed. There are no auto-renewals, a real prescriber reads your update, not a system running on autopilot. The full titration context, including how each dose fits into the schedule, is laid out on our Wegovy doses page if you want a clearer picture of the road ahead.